3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Carcinoma, Non-Small-Cell Lung
35
Breast Neoplasms
34
Lung Neoplasms
20
Triple Negative Breast Neoplasms
6
Neoplasm Metastasis
5
Adenocarcinoma of Lung
5
Uterine Cervical Neoplasms
4
Rhabdomyosarcoma
3
Neoplasms
3
NSCLC
3
Hodgkin Disease
3
Rhabdomyosarcoma, Embryonal
2
Rhabdomyosarcoma, Alveolar
2
Recurrence
2
Adenocarcinoma
2
Thoracic Neoplasms
1
Sarcoma
1
Respiratory Tract Neoplasms
1
Respiratory Tract Diseases
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Non - Small Cell Lung Cancer NSCLC
1
Neuralgia
1
Metastatic HER2-positive Breast Cancer
1
Mesothelioma, Malignant
1
Malignant mesenchymal tumor
1
Lymphoma, Non-Hodgkin
1
Lymphoma
1
Lung Diseases
1
HR+HER2- Breast Cancer
1
HER2-positive Advanced Breast Cancer
1
Interventions
Pemetrexed
3
Carboplatin
3
pembrolizumab
2
patritumab
1
osimertinib
1
napabucasin
1
camrelizumab
1
aflutinib
1
Vinorelbine
1
TNFSF10 protein, human
1
Paclitaxel
1
Injections
1
Gemcitabine
1
Erlotinib Hydrochloride
1
Docetaxel
1
Cisplatin
1
Bevacizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Bronchial Neoplasms
×
Vinorelbine
×
Clear all
NCT03402048
2020-11-04
EPIC
University of Turin, Italy
Phase 3
Unknown
567 enrolled